FDA Clears First Smart Ring for Continuous Blood Pressure Tracking Without Inflatable Cuffs
Washington, Monday, 5 October 2026.
Happy Health secured milestone FDA clearance for cuffless blood pressure monitoring. Clinical trials revealed nighttime systolic readings are nearly six times more predictive of cardiovascular mortality than traditional clinic measurements.
Clinical Validation and Accuracy Standards
The regulatory approval follows a rigorous validation process involving 850 paired measurements across 85 patients, ranging from normal blood pressure to Stage 2 hypertension [1]. Clinical validation results demonstrated a mean error of 0.8 mmHg for systolic blood pressure and 0.1 mmHg for diastolic blood pressure when validated against invasive arterial-line measurements as the clinical reference standard [1]. This level of precision is critical given that observational cohort analysis indicated nighttime systolic blood pressure is 5.91 times more informative than clinic measurements for predicting all-cause mortality [1]. Furthermore, the data suggests nighttime readings are 6.04 times more informative for cardiovascular death, highlighting the importance of continuous monitoring over occasional checks [1]. The difference in predictive power for cardiovascular death compared to all-cause mortality is 0.13 times, underscoring the specific value of nocturnal data [1].
Market Positioning and Competitive Landscape
Happy Health enters a competitive wearable blood pressure space that includes entities like Whoop, Oura, Apple, and Samsung, though many competitors focus primarily on optical sensors without full FDA clearance for cuffless measurement [3]. Unlike Huawei, which secured a CE Mark for a mini-cuff watch, Happy Health’s technology eliminates the need for inflatable cuffs entirely [3]. The company previously secured FDA clearance for the Happy Ring Health Monitoring System on September 24, 2024, followed by clearance for the Happy Health Home Sleep Test software on June 18, 2025 [2]. This latest clearance allows the device to track two major cardiovascular disease risk factors with data routed to a physician network, distinguishing it from consumer-grade wellness trackers [3]. The Happy Ring platform utilizes AI to analyze over 2.8 million medical data points nightly across respiratory, cardiovascular, neurological, and metabolic systems [1].
Funding and Commercial Rollout Timeline
To support the development of its diagnostic smart ring, Happy Health raised $75 million in funding in August 2026 from investors including ARCH Venture Partners and OpenLoop [1][3]. This follows an earlier $60 million Series A funding round led by ARCH Venture Partners announced in August 2022, bringing the total disclosed funding from these specific rounds to 135 million dollars [2][3]. The company plans to initiate a phased commercial rollout of the FDA-cleared blood pressure tracking features via a firmware update to existing users starting October 15, 2026 [3]. Happy Health maintains a 50-state physician network to interpret clinical data and manage patient diagnosis, facilitating the transition from raw data to actionable medical insights [1]. The device is currently positioned as a provider of physician-guided home sleep testing with a published self-pay cost of $396 for the test, excluding treatment fees [2].